Stimvia Expands Science Advisory Board and Global Leadership for URIS® Therapy Growth

Stimvia's Strategic Expansion

Stimvia, a Czech medical technology company specializing in non-invasive neuromodulation therapies for overactive bladder (OAB), has recently taken significant steps to enhance its market presence and credibility in the global healthcare landscape. On May 13, 2026, the company announced the expansion of its Scientific Advisory Board as well as an increase in its international commercial leadership team to accelerate the growth of its flagship therapy, URIS®.

Strengthening Clinical and Scientific Considerations

The expansion of the Scientific Advisory Board represents a strategic initiative by Stimvia to align its clinical strategies with top experts in urology. By collaborating with leading professionals from the United States, the United Kingdom, and across Europe, Stimvia aims to fortify its clinical credibility and enhance the global adoption of URIS®.

Among the newly appointed advisors is David R. Staskin, a notable urologist based in Boston, who brings extensive expertise in developing medical devices and conducting clinical studies related to lower urinary tract disorders. His involvement is expected to provide foundational knowledge that can guide product development and clinical outcomes.

Also joining the board is Alan J. Wein, MD, PhD, a distinguished authority in the field of overactive bladder with a former position as the head of the urology department at the University of Pennsylvania. His contributions to international treatment guidelines make him an invaluable asset to the company.

The board also features Christopher R. Chapple, an internationally recognized figure in functional and reconstructive urology, based in the UK, and Bertil Blok, a leading specialist in neuro-urology from the Netherlands. Their collective insights position Stimvia to engage effectively with clinical counterparts and reinforce trust among health sector partners and investors.

Building a Robust Global Commercial Engine

As part of its mission to penetrate international markets, Stimvia has attracted seasoned commercial leadership to streamline its global distribution and development efforts. David da Silva has been appointed as the Head of Global Distribution and Market Development, bringing over ten years of commercial leadership experience from renowned MedTech companies such as Medtronic, Stryker, and Ascendis Health. His focus will be on scalable distribution partnerships and strategic market entries across key regions including Europe and Latin America.

Additionally, Alim Topdag, MSc, has taken on the role of Director of Sales and Business Development for markets outside the United States. His role is pivotal in driving sales strategies, building partnerships with distributors, and nurturing direct business models that support clinical implementation and therapy adoption.

By synergizing premier clinical advisory with expanded commercial leadership, Stimvia is setting the stage for a strategic and robust approach to facilitating the global penetration of URIS®. This dual alignment not only bolsters confidence among investors but also enhances the potential for clinical adoption in international markets.

Conclusion

As Stimvia moves forward with these expansions, its focus remains on providing effective therapy options for patients suffering from overactive bladder conditions. With a well-rounded leadership team and enhanced scientific guidance, the company is well-positioned to fulfill its mission of improving healthcare solutions on a global scale. The next few years are expected to prove pivotal as URIS® gains traction in various markets worldwide.